Nonclassic endogenous regulators of angiogenesis

Pharmacological Reviews

Volumn 59, Issue 2, 2007, Pages 185-205

  Ribatti, Domenico ^a,c   Conconi, Maria Teresa ^b   Nussdorfer, Gastone G ^b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ADIPONECTIN; ANGIOPOIETIN 1; ANGIOSTATIN; ANGIOTENSIN II; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOSTATIN; ENDOTHELIN; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LEPTIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NEUROPEPTIDE Y; PLATELET DERIVED GROWTH FACTOR; RESISTIN; SUBSTANCE P; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UROTENSIN II; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; BLOOD VESSEL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; ERYTHROCYTE; ERYTHROPOIESIS; EXTRACELLULAR MATRIX; HEREDITY; HINDLIMB; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMB ISCHEMIA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES;

EID: 34249785108     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.59.2.3     Document Type: Review

References (294)

1. Abasolo I, Montuenga LM, and Calvo A (2006) Adrenomedullin prevents apoptosis in prostate cancer cells. Regul Pept 133:115-122.
2. Abe M, Sata M, Nishimatsu H, Nagata D, Suzuki E, Terauchi Y, Kadowaki T, Minamino N, Kangawa K, Matsuo H, et al. (2003) Adrenomedullin augments collateral development in response to acute ischemia. Biochem Biophys Res Commun 306:10-15.
3. Abe M, Sata M, Suzuki E, Takeda R, Takahashi M, Nishimatsu H, Nagata D, Kangawa K, Matsuo H, Nagai R, et al. (2006) Effects of adrenomedullin on acute ischaemia-induced collateral development and mobilization of bone-marrow derived cells. Clin Sci 111:381-387.
4. Adachi Y, Takeuchi T, Sonobe H, and Ohtsuki Y (2006) An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways. Virchows Arch 448:311-318.
5. Ahima RS and Flier JS (2000) Leptin. Annu Rev Physiol 62:413-437.
6. Ahmed SI, Thompson J, Coulson JM, and Woll PJ (2000) Studies on the expression of endothelin, its receptor subtypes and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 22:422-431.
7. Albertin G, Rucinski M, Carraro G, Forneris M, Andreis PG, Malendowicz LK, and Nussdorfer GG (2005) Adrenomedullin and vascular endothelium growth factor genes are overexpressed in the regenerating rat adrenal cortex, and AM and VEGF reciprocally enhance their mRNA expression in cultured rat adrenocortical cells. Int J Mol Med 16:431-435.
8. Albertin G, Ruggero M, Guidolin D, and Nussdorfer GG (2006) Gene silencing of human RAMP2 mediated by short-interfering RNA. Int J Mol Med 18:531-535.
9. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, et al. (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan GPR14. Nature 401:282-286.
10. Anagnostou A, Lee ES, Kessimian N, Levinson R, and Steiner M (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87:5978-5982.
11. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, and Noguchi CT (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 91:3974-3978.
12. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumata M, Hotta K, Nishida M, Takahashi M, et al. (2002) Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893-2898.
13. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, Burnstock G, and Taylor I (2001) Increased endothelin-1 in colorectal cancer and reduction of tumor growth by ET(A) receptor antagonism. Br J Cancer 85:1759-1763.
14. Ashley RA, Dubuque SH, Dvorak B, Woodward SS, William SK, and Kling PT (2002) Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr Res 51:472-478.
15. Bagnato A, Rosanó L, Di Castro V, Albini A, Salani D, Varmi M, Nicotra MR, and Natali PG (2001) Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am J Pathol 158:841-847.
16. Bagnato A and Spinella F (2003) Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 14:44-50.
17. Baiguera S, Conconi MT, Guidolin D, Mazzocchi G, Malendowicz LK, Parnigotto PP, Spinazzi R, and Nussdorfer GG (2004) Ghrelin inhibits in vitro angiogenic activity of rat brain microvascular endothelial cells. Int J Mol Med 14:849-854.
18. Balasubramaniam A (1997) Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides 18:445-457.
19. Baldanzi G, Filigheddu N, Cutrupi B, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, et al. (2002) Ghrelin and desacyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI3-kinase/AKT. J Cell Biol 159:1029-1037.
20. Balkwill F and Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545.
21. Basilico C and Moscatelli D (1992) The FGF family of growth factors and oncogenes. Adv Cancer Res 59:115-165.
22. Belloni AS, Albertin G, Forneris M, and Nussdorfer GG (2001) Pro-adrenomedullin derived peptides as autocrine-paracrine regulators of cell growth. Histol Histopathol 16:1263-1274.
23. Belloni AS, Guidolin D, Salmaso R, Bova S, Rossi GP, and Nussdorfer GG (2005) Adrenomedullin, ANP and BNP are colocalized in a subset of endocrine cells in the rat heart. Int J Mol Med 15:567-571.
24. Belloni AS, Macchi C, Rebuffat P, Conconi MT, Malendowicz LK, Parnigotto PP, and Nussdorfer GG (2004) Effects of ghrelin on the apoptotic deletion rate of different types of cells cultured in vitro. Int J Mol Med 14:165-167.
25. Belloni AS, Petrelli L, Guidolin D, De Toni R, Bova S, Spinazzi R, Gerosa G, Rossi GP and Nussdorfer GG (2006) Identification and localization of adrenomedullin-storing cardiac mast cells. Int J Mol Med 17:709-713.
26. 2+-dependent agonist-stimulated secretion of human adrenal glands. Hypertension 33:1185-1189.
27. Bełtowski J (2003) Adiponectin and resistin: new hormones of white adipose tissue. Med Sci Monit 9:RA55-RA61.
28. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, and Engert A (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive metaanalysis. J Natl Cancer Inst 97:489-498.
29. Bouloumié A, Drexler HCA, Lafontan M, and Busse R (1998) Leptin, the product of ob gene, promotes angiogenesis. Circ Res 83:1059-1066.
30. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, and Cao Y (2004) Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 101:2476-2481.
31. Brooks PC, Clark RAF, and Cheresh DA (1994) Requirement of vascular integrin αvβ3 for angiogenesis. Science 264:569-571.
32. Brooks PC, Stromblad S, Sanders LC, Von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, and Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interactions with integrin αvβ3. Cell 85:683-693.
33. Calabro P, Samudio I, Willerson JT, and Yeh ETH (2004) Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110:3335-3340.
34. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, and Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100:4802-4806.
35. Camiña JP (2006) Cell biology of the ghrelin receptor. J Neuroendocrinol 18:65-76.
36. Cao JM, Ong H, and Chen C (2006) Effects of ghrelin and synthetic GH secretagogue on the cardiovascular system. Trends Endocrinol Metab 17:13-18.
37. Cao R, Bråkenhielm E, Wahlestedt C, Thyberg J, and Cao Y (2001) Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A 98:6390-6395.
38. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, and Rothstein M (1993) Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43:1010-1014.
39. Carlini RG, Reyes AA and Rothstein M (1995) Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47:740-745.
40. Caron KM and Smithies O (2001) Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci U S A 98:615-619.
41. Cascinu S, Del Ferro E, Ligi M, Staccioli MP, Giordani P, Catalano V, Agostinelli R, Muretto P, and Catalano G (2001) Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 19:8-12.
42. 2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer 31:203-212.
43. Cerdá-Reverter JM and Larhammar D (2000) Neuropeptide Y family of peptides: structure, anatomical expression, function, and molecular evolution. Biochem Cell Biol 78:371-392.
44. Chua CC, Hamdy RC, and Chua BH (1998) Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1401:187-194.
45. Chun YS, Hyun JY, Kwak YG, Kim IS, Kim CH, Choi E, Kim MS, and Park JW (2003) Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 370:149-157.
46. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Müller C, et al. (2004) Pharmacology of the urotensin II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4- hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311:204-212.
47. Cohen B, Barkan D, Levy Y, Goldberg I, Fridman E, Kopolovic J, and Rubinstein M (2001) Leptin induces angiopoietin-2 expression in adipose tissues. J Biol Chem 276:7697-7700.
48. Collado B, Gutierrez-Cañas I, Rodriguez-Henche N, Prieto JC, and Carmena MJ (2004) Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 119:69-75.
49. 2+ signalling: implication in angiogenesis and neuroendocrine differentiation. Biochim Biophys Acta 1744:224-233.
50. Collado B, Sanchez-Chapado M, Prieto JC, and Carmena MJ (2006) Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Mol Cell Endocrinol 249:116-122.
51. Conconi MT, Nico B, Guidolin D, Baiguera S, Spinazzi R, Rebuffat P, Malendowicz LK, Vacca A, Carraro G, Parnigotto PP, et al. (2004) Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo. Peptides 25:2179-2185.
52. Conconi MT, Spinazzi R, and Nussdorfer GG (2006) Endogenous ligands of PACAP/VIP receptors in the autocrine-paracrine regulation of the adrenal gland. Int Rev Cytol 249:1-51.
53. Cormier-Regards S, Nguyen SV, and Claycomb WC (1998) Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem 273:17787-17792.
54. Crandall DL, Hausman GJ, and Kral JG (1997) A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 4:211-232.
55. Cross MJ and Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201-207.
56. Cruz A, Parnot C, Ribatti D, Corvol P, and Gasc JM (2001) Endothelin-1, a regulator of angiogenesis in the chick chrioallantoic membrane. J Vasc Res 38:536-545.
57. Cruze CA, Su F, Limberg BJ, Deutch AJ, Stoffolano PJ, Dai HJ, Buchanan DD, Yang HT, Terjung RL, Spruell RD, et al. (2007) The Y2 receptor mediates increases in collateral-dependent blood flow in a model of peripheral arterial insufficiency. Peptides 28:269-280.
58. Csaba Z and Dournaud P (2001) Cellular biology of somatostatin receptors. Neuropeptides 35:1-23.
59. Curtis SB, Hewitt J, Yakubovits S, Anzarut A, Hsiang YN, and Buchan AMJ (2000) Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol 278:H1815-H1822.
60. Dameron KM, Volpert OV, Tainsky MA, and Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584.
61. D'Andrea LD, Del Gatto A, Pedone C, and Benedetti E (2006) Peptide-based molecules in angiogenesis. Chem Biol Drug Des 67:115-126.
62. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, and Tacca MD (1997) Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 3:265-272.
63. Davenport AP (2002) International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54:219-226.
64. Davenport AP and Maguire JJ (2000) Urotensin II: fish neuropeptide catches orphan receptor. Trends Pharmacol Sci 21:80-92.
65. Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, and Kangawa K (2005) International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution and function. Pharmacol Rev 57:541-546.
66. Dhanabal M, Ramachandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, and Sukhatme VP (1999) Endostatin induces endothelial cell apoptosis. J Biol Chem 274:11721-11726.
67. Dimmeler S and Zeiher AM (2000) Akt takes center stage in angiogenesis signaling. Circ Res 86:4-5.
68. Djonov V, Schmid M, Tschanz SA, and Burri PH (2000) Intussusceptive angiogenesis: its role in embryonic vascular network formation. Circ Res 86:286-292.
69. D'Orléans-Juste P, Labonté J, Bkaily G, Choufani S, Plante M, and Honorè JC (2002) Function of the endothelin B receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 95:221-238.
70. Douglas SA and Ohlstein EH (2000) Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10:229-237.
71. Egidy G, Eberl LP, Valdenaire O, Irmler M, Majdi R, Diserens AC, Fontana A, Janzer RC, Pinet F, and Juillerat-Jeanneret L (2000a) The endothelin system in human glioblastoma. Lab Invest 80:1681-1689.
72. Egidy G, Juillerat-Jeanneret L, Jeannin JF, Korth P, Bosman FT, and Pinet F (2000b) Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol 157:1863-1874.
73. Fabre JE, Rivard A, Magner M, Silver M, and Isner JM (1999) Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 99:3043-3049.
74. Fagan KA, McMurthry IF, and Rodman DM (2001) Role of endothelin-1 in lung disease. Respir Res 2:90-101.
75. Fan TP, Hu DE, Guard S, Gresham GA, and Watling KJ (1993) Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists. Br J Pharmacol 110:43-49.
76. Farrell F and Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. The Oncologist 9 (Suppl 5):18-30.
77. Feoktistov I, Ryzhov S, Goldstein AE, and Biagioni I (2003) Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. Circ Res 92:485-492.
78. Fernandez LA, Twickler J, and Mead A (1985) Neovascularization produced by angiotensin II. J Lab Clin Med 105:141-145.
79. Fernandez-Sauze S, Delfino C, Mabrouk K, Dussert C, Chinot O, Martin PM, Grisoli F, Ouafik L, and Boudouresque F (2004) Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 108:797-804.
80. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611.
81. Ferrara N, Gerber HP, and Le Couter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676.
82. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, et al. (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144:1574-1584.
83. Flynn MA, Haleen SJ, Welch KM, Cheng XM, and Reynolds EE (1998) Endothelin B receptors on human endothelial and smooth muscle cells show equivalent binding pharmacology. J Cardiovasc Pharmacol 32:106-116.
84. Folkman J (1995) Angiogenesis in cancer, vascular rheumatoid and other diseases. Nat Med 1:27-32.
85. Folkman J (2006) Angiogenesis. Annu Rev Med 57:1-18.
86. Forneris M, Gottardo L, Albertin G, Malendowicz LK, and Nussdorfer GG (2001) Expression and function of adrenomedullin and its receptors in Conn's adenoma cells. Int J Mol Med 8:675-679.
87. Frede S, Freitag P, Otto T, Heilmaier C, and Fandrey J (2005) The proinflammatory cytokine interleukin 1β and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation. Cancer Res 65:4690-4697.
88. Fujitani Y, Oda K, Takimoto M, Inui T, Okada T, and Urade Y (1992) Autocrine receptors for endothelins in the primary culture of endothelial cells of human umbilical vein. FEBS Lett 298:79-83.
89. Garayoa M, Martínez A, Lee S, Pio R, An WG, Neckers L, Trepel J, Montuenga LM, Ryan H, Johnson R, et al. (2000) Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 14:848-862.
90. García MA, Martin-Santamaria S, De Pascual-Teresa B, Ramos A, Julian M, and Martínez A (2006) Adrenomedullin: a new and promising target for drug discovery. Expert Opin Ther Targets 10:303-317.
91. Garcia de la Torre N, Wass JAH, and Turner HE (2002) Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 57:425-441.
92. Ghezzi P and Brines M (2004) Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 11:537-544.
93. Goligorsky MS, Budzikowski AS, Tsukahara H, and Noiri E (1999) Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 26:269-271.
94. Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, et al. (2006) Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 281:26320-26328.
95. González-Santiago L, Lopez-Ongil S, Griera M, Rodriguez-Puyol M, and Rodriguez-Puyol D (2002) Regulation of endothelin synthesis by extracellular matrix in human endothelial cells. Kidney Int 62:537-543.
96. Good DJ, Polverini PJ, Rastinejad F, Lebeau MM, Lemons RS, Frazier WA, and Bouck NP (1990) A tumor-suppressor dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 87:6624-6628.
97. Green H and Kehinde O (1979) Formation of normally differentiated subcutaneous fat pads by an established preadipose cell line. J Cell Physiol 101:169-171.
98. Gulec SA, Drouant GJ, Fuselier J, Anthony CT, De Heneghan JI, Carpio JB, Coy DH, Murphy WA, and Woltering EA (2001) Antitumor and antiangiogenic effects of somatostatin receptor-targeted in situ radiation with (111)In-DTPA-JIC 2DL. J Surg Res 97:131-137.
99. Hague S, Zhang L, Oehler MK, Manek S, MacKenzie IZ, Bicknell R, and Rees MC (2000) Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma (benign smooth muscle tumors) vascular density. Clin Cancer Res 6:2808-2814.
100. Haller H, Christel C, Donnenberg L, Thiele P, Lindschau C, and Luft FC (1996) Signal transduction of erythropoietin in endothelial cells. Kidney Int 50:481-488.
101. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, and Dewhirst MW (2006) Erythropoietin biology in cancer. Clin Cancer Res 12:332-339.
102. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Szeedharan SP, et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265-270.
103. Harrison S and Geppetti P (2001) Substance P. Int J Biochem Cell Biol 33:355-376.
104. Hata K, Takebayashi Y, Akiba S, Fujiwara R, Iida K, Nakayama K, Fukumoto M, and Miyazaki K (2000) Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 6:867-872.
105. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, and Dimmeler S (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340-1346.
106. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schlcher B, Mose S, Beer KT, Burger U, Dougherty C, et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260.
107. Hinson JP, Kapas S, and Smith DM (2000) Adrenomedullin a multifunctional regulatory peptide. Endocr Rev 21:138-167.
108. Hiromatsu Y and Toda S (2003) Mast cells and angiogenesis. Microsc Res Tech 60:64-69.
109. Hirschi KK, Rohovsky SA, and D'Amore PA (1998) PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141:805-814.
110. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, and De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549-580.
111. Hu D, Hiley CR, and Fan TP (1996) Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model. Br J Pharmacol 117:545-551.
112. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, and Lodish HF (2004) T-cadherin is a receptor for hexameric and high molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 101:10308-10313.
113. Hültner L and Ehrenreich H (2005) Mast cells and endothelin-1: a life-saving biological liason? Trends Immunol 26:235-238.
114. Iimuro S, Shindo T, Moriyama N, Amaki T, Niu P, Takeda N, Iwata H, Zhang Y, Ebihara A, and Nagai R (2004) Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 95:415-423.
115. Iruela-Arispe ML, Bornstein P, and Sage H (1991) Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A 88:5026-5030.
116. Itoh H, Pratt RE, and Dzau VJ (1992) Atrial natriuretic peptide as a novel antigrowth factor of endothelial cells. Hypertension 19:758-761.
117. Ivanov D, Philippova M, Allenspach R, Erne P, and Resink T (2004) T-cadherin upregulation correlates with cell-cycle progression and promotes proliferation of vascular cells. Cardiovasc Res 64:132-143.
118. Iwase T, Nagaya N, Fujii T, Itoh T, Ishibashi-Ueda H, Yamagishi M, Miyatake K, Matsumoto T, Kitamura S, and Kangawa K (2005) Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia. Circulation 111:356-362.
119. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, and Kuck KH (2002) Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64:326-333.
120. Jelkmann W (2004) Molecular biology of erythropoietin. Intern Med 43:646-659.
121. Jimenez N, Abasolo I, Jongsma J, Calvo A, Garayoa M, Van der Kwast TH, Van Steenbrugge GJ, and Montuenga LM (2003) Androgen-independent expression of adrenomedullin and peptidylglycine α-amidating monooxigenase in human prostatic carcinomas. Mol Carcinogen 38:14-24.
122. Julián M, Cacho M, García MA, Martin-Santamaria S, De Pascual-Teresa B, Ramos A, Martínez A, and Cuttitta F (2005) Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities. Eur J Med Chem 40:737-750.
123. Kadowaki T and Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439-451.
124. Kamohara M, Matsuo A, Takasaki J, Kohda M, Matsumoto M, Matsumoto SI, Soga T, Hiyama H, Kobori M, and Katou M (2005) Identification of MrgX2 and a human G protein-coupled receptor for proadrenomedullin N-terminal peptide. Biochem Biophys Res Commun 330:1146-1152.
125. Kandel J, Bossy-Wetzel E, Raduvanyi F, Kalgsbrun M, Folkman J, and Hanahan D (1991) Neovascularization is associated with a switch to export of FGF-2 in the multistep development of fibrosarcoma. Cell 66:1095-1104.
126. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, Tuomainen TP, Kauhanen J, Nyyssönen K, Lakka HM, et al. (2001) Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 159:145-151.
127. Kato J, Tsuruda T, Kita T, Kitamura K, and Eto T (2005) Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 25:2480-2487.
128. Kedzierski RM and Yanagisawa M (2001) Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol 41:851-876.
129. Kim W, Moon SO, Lee S, Sung MJ, Kim SH, and Park SK (2003a) Adrenomedullin reduces VEGF-induced endothelial adhesion molecules and adhesiveness through a phosphatidylinositol 3′-kinase pathway. Arterioscler Thromb Vasc Biol 23:1377-1383.
130. Kim W, Moon SO, Sung MJ, Kim SH, Lee SO, So JN, and Park SK (2003b) Angiogenic role of adrenomedullin through activation of Akt mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J 13:1937-1939.
131. Kim YM, Jang JW, Lee OH, Yeaon J, Choi EY, Kim KW, Lee ST, and Kwon YG (2000) Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60:5410-5413.
132. Kitlinska J (2007) Neuropeptide Y (NPY) in neuroblastoma: effect on growth and vascularization. Peptides 28:405-412.
133. Kitlinska J, Lee EW, Movafagh S, Pons J, and Zukowska Z (2002) Neuropeptide Y-induced angiogenesis in aging. Peptides 23:71-77.
134. Kobashi C, Urakaze M, Kishida M, Kibayashi E, Kobayashi H, Kihara S, Funahashi T, Takata M, Temaru R, Sato A, et al. (2005) Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97:1245-1252.
135. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, and Matsuzawa Y (2004) Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:27-31.
136. Kojima M, Hosoda H, Matsuo H, and Kangawa K (2001) Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 12:118-122.
137. Kojima M and Kangawa K (2005) Ghrelin: structure and function. Physiol Rev 85:495-522.
138. Koury MJ (2005) Erythropoietin: the story of hypoxia and a finely regulated hematopoietic hormone. Exp Hematol 33:1263-1270.
139. 2+ influx. Acta Physiol Scand 183:161-169.
140. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, et al. (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89.
141. Kuo LE and Zukowska Z (2007) Stress, NPY and vascular remodeling: implications for stress-related diseases. Peptides 28:435-440.
142. Kusaka Y, Kelly RA, Williams GH, and Kifor I (2000) Coronary microvascular endothelial cells cosecrete angiotensin II and endothelin-1 via a regulated pathway. Am J Physiol 279:H1087-H1096.
143. Lawler J (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1-12.
144. Le Noble FAC, Hekking JWM, Van Straaten HWM, Slaaf DW, and Struyker-Boudier HAJ (1991) Angiotensin II stimulates angiogenesis in the chorioallantoic membrane of the chick embryo. Eur J Pharmacol 195:3005-3006.
145. Lee EW, Grant DS, Movafagh S, and Zukowska Z (2003) Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 24:99-106.
146. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, and Betsholtz C (1994) Mice deficient for PDGF-B show renal, cardiovascular and hematological abnormalities. Gene Dev 8:1875-1887.
147. Levin ER, Gardner DG, and Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321-328.
148. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459-460.
149. Li J, Zhang YP, and Kirsner RS (2003a) Angiogenesis in wound repair: angiogenic growth factor and the extracellular matrix. Microsc Res Tech 60:107-114.
150. Li L, Lee EW, Ji H, and Zukowska Z (2003b) Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery. Arterioscler Thromb Vasc Biol 23:1204-1210.
151. Li Z, Takeuchi S, Otani T, and Maruo T (2001) Implications of adrenomedullin expression in the invasion of squamous cell carcinoma of the uterine cervix. Int J Clin Oncol 6:263-270.
152. Lindahl P, Johansson BR, Levéen P, and Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B deficient mice. Science 277:242-245.
153. López J and Martínez A (2002) Cell and molecular biology of the multifunctional peptide adrenomedullin. Int Rev Cytol 221:1-92.
154. Mahmud DL, Amlak M, Deb DK, Platanias LC, Uddin S, and Wickrema A (2002) Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene 21:1556-1562.
155. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60.
156. Martínez A, Bengoechea JA, and Cuttitta F (2006) Molecular evolution of proadrenomedullin N-terminal 20 peptide (PAMP): evidence for gene co-option. Endocrinology 147:3457-3461.
157. Martínez A, Vos M, Guedez L, Kaur G, Chen Z, Garayoa M, Pio R, Moody T, Stetler-Stevenson WG, Kleinman HK, et al. (2002) The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 94:1226-1237.
158. 2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth. Cancer Res 64:6489-6494.
159. Masuzaki H, Ogawa Y, Sagawa N, Hosoda K, Matsumoto T, Mise H, Nishimura H, Yoshimasa Y, Tanaka I, Mori T, et al. (1997) Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med 3:1029-1033.
160. Matsusaka T and Ichikawa I (1997) Biological functions of angiotensin and its receptor. Annu Rev Physiol 59:375-412.
161. Matsuura A, Yamochi W, Hirata K, Kawashima S, and Yokoyama M (1998) Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 32:89-95.
162. Maurer M, Wedemeyer J, Metz M, Piliponsky AM, Weller K, Chatterjea D, Clouthier DE, Yanagisawa MM, Tsai M, and Galli SJ (2004) Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432:512-516.
163. Mazzocchi G, Malendowicz LK, Ziolkowska A, Spinazzi R, Rebuffat P, Aragona F, Ferrazzi E, Parnigotto PP, and Nussdorfer GG (2004) Adrenomedullin (AM) and AM receptor type-2 expression is up-regulated in prostate carcinomas (PC), and AM stimulates in vitro growth of a PC-derived cell line by enhancing proliferation and decreasing apoptosis rates. Int J Oncol 25:1781-1787.
164. Mentlein R, Eichler O, Forstreuter F, and Held-Feindt J (2001) Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 92:545-550.
165. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, and Westfall T (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50:143-150.
166. Mignatti P and Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195.
167. Miyashita K, Itoh H, Arai H, Suganami T, Sawada N, Fukunaga Y, Sone M, Yamahara K, Yurugi-Kobayashi T, Park K, et al. (2006) The neuroprotective and vasculo-neuro-regenerative roles of adrenomedullin in ischemic brain and its therapeutic potential. Endocrinology 147:1642-1653.
168. Miyashita K, Itoh H, Sawada N, Fukunaga Y, Sone M, Yamahara K, Yurugi-Kobayashi T, Park K, and Nakao K (2003) Adrenomedullin provokes endothelial Akt activation and promotes vascular regeneration both in vitro and in vivo. FEBS Lett 544:86-92.
169. Mohamed-Ali V, Pinkney JH, and Coppack SW (1998) Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 22:1145-1158.
170. Molet S, Furukawa K, Maghazechi A, Hamid Q, and Giaid A (2000) Chemokine and cytokine-induced expression of endothelin-1 and endothelin converting enzyme-1 in endothelial cells. J Allergy Clin Immunol 105:333-338.
171. Moody TW, Leyton J, Casibang M, Pisegna J, and Jensen RT (2002) PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Regul Pept 109:135-140.
172. Morbidelli L, Orlando C, Maggi CA, Ledda F, and Ziche M (1995) Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol 269:H685-H695.
173. Movafagh S, Hobson JP, Spiegel S, Kleinman HK, and Zukowska Z (2006) Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J 20:1327-1337.
174. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, and Chen C (2006) Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 70:146-157.
175. Müller-Ehmsen J, Schmidt A, Krausgrill B, Schwinger RHG, and Bloch W (2006) Role of erythropoietin for angiogenesis and vasculogenesis: from embryonic development through adulthood. Am J Physiol 290:H331-H340.
176. Nagaya N, Mori H, Mutokami S, Kangawa K, and Kitamura S (2005) Adrenomedullin: angiogenesis and gene therapy. Am J Physiol 288:R1432-R1437.
177. Nakayama M, Takahashi K, Murakami O, Shirato K, and Shibahara S (1998) Induction of adrenomedullin by hypoxia and cobalt chloride in human colorectal carcinoma cells. Biochem Biophys Res Commun 243:514-517.
178. Nguyen SV and Claycomb WC (1999) Hypoxia regulates the expression of adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem Biophys Res Commun 265:382-386.
179. Nikitenko LL, Fox SB, Kekoe S, Rees MCP, and Bicknell R (2006) Adrenomedullin and tumor angiogenesis. Br J Cancer 94:1-7.
180. Nikitenko LL, Smith DM, Hague S, Wilson CR, Bicknell R, and Rees MCP (2002) Adrenomedullin and the microvasculature. Trends Pharmacol Sci 23:101-103.
181. Niskanen L, Karvonen MK, Valve R, Koulu M, Pesonen U, Mercuri M, Rauramaa R, Töyry J, Laakso M, and Uusitupa MIJ (2000) Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 85:2266-2269.
182. Noiri E, Hu Y, Bahou WF, Keese CR, Giaever I, and Goligorsky MS (1997) Permissive role of nitric oxide in endothelin-induced migration of endothelial cells. J Biol Chem 272:1747-1752.
183. Noiri E, Lee E, Testa J, Quigley J, Colflesh D, Keese CR, Giaever I, and Goligorsky MS (1998) Podokinesis in endothelial cell migration: role of NO. Am J Physiol 274:C236-C244.
184. Nothacker HP, Wang Z, Zeng H, Mahata SK, O'Connor DT, and Civelli O (2005) Proadrenomedullin N-terminal peptide and corticostatin activation of MrgX2 receptor is based on a common structural motif. Eur J Pharmacol 519:191-193.
185. Nussdorfer GG (2001) Proadrenomedullin-derived peptides in the paracrine control of the hypothalamo-pituitary-adrenal axis. Int Rev Cytol 206:249-284.
186. Nussdorfer GG and Malendowicz LK (1998) Role of tachykinins in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 19:949-968.
187. Nussdorfer GG, Rossi GP, Malendowicz LK, and Mazzocchi G (1999) Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Pharmacol Rev 51:403-438.
188. Oehler MK, Fischer DC, Orlowska-Volk M, Herrie F, Kiebach DG, Rees MC, and Bicknell R (2003) Tissue and plasma expression of the angiogenic peptide adrenomedullin in the breast cancer. Br J Cancer 89:1927-1933.
189. Oehler MK, Hague S, Reese MC, and Bicknell R (2002) Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 21:2815-2821.
190. Oehler MK, Norbury C, Hague S, Rees MC, and Bicknell R (2001) Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 20:2937-2945.
191. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, et al. (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770.
192. Okuda Y, Tsurumaru K, Suzuki S, Miyauchi T, Asano M, Hong Y, Sone H, Fujita R, Mizutani M, Kawakami Y, et al. (1998) Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci 63:477-484.
193. Olias G, Viollet C, Kusserow H, Epelbaum J, and Meyerhof W (2004) Regulation and function of somatostatin receptors. J Neurochem 89:1057-1091.
194. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
195. O'Reilly MS, Holmgren L, Chen C, and Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692.
196. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, and Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328.
197. Ortega S, Ittmann SH, Tsang M, Ehrlich M, and Basilico C (1998) Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor-2. Proc Natl Acad Sci U S A 95:5672-5677.
198. Otani A, Takagi H, Suzuma K, and Honda Y (1998) Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 82:619-628.
199. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, Funahashi T, and Walsh K (2004) Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279:1304-1309.
200. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999-1007.
201. Patel Y (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198.
202. Pedram A, Hu RM, and Levin ER (1997a) Vasoactive peptides modulate vascular endothelial growth factor production and endothelial cell proliferation and invasion. J Biol Chem 272:17097-17103.
203. Pedram A, Razandi M, Hu RM, and Levin ER (1997b) Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 272:17097-17103.
204. Pedram A, Razandi M, and Levin ER (2001) Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis. Endocrinology 142:1578-1586.
205. Pepper MS (1997) Manipulating angiogenesis: from basic science to the bedside. Arterioscler Thromb Vasc Biol 17:605-619.
206. Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, and Montesano R (1994) Modulation of bovine microvascular endothelial cell proteolytic properties by inhibition of angiogenesis. J Cell Biochem 55:419-434.
207. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, and Foord SM (2002) International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54:233-246.
208. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, and Rusnati M (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16:159-178.
209. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, and Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932-939.
210. Ren B, Yee KO, Lawler J and Khosravi-Far R (2006) Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 1765:178-188.
211. Rhodin JAG and Fujita H (1989) Capillary growth in mesentery of normal young rats. Intravital video and electron microscope analyses. J Submicrosc Cytol Pathol 21:1-34.
212. Ribatti D (2005) The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 128:303-309.
213. Ribatti D (2006) Genetic and epigenetic mechanisms in the early development of the vascular system. J Anat 208:139-152.
214. Ribatti D, Guidolin D, Conconi MT, Nico B, Baiguera S, Parnigotto PP, Vacca A, and Nussdorfer GG (2003a) Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. Oncogene 22:6458-6461.
215. Ribatti D, Nico B, Belloni AS, Vacca A, Roncali L, and Nussdorfer GG (2001) Angiogenic activity of leptin in the chick embryo chorioallantoic membrane is in part mediated by endogenous fibroblast growth factor-2. Int J Mol Med 8:265-268.
216. Ribatti D, Nico B, Crivellato E, Roccaro AM, and Vacca A (2007) The history of the angiogenic switch concept. Leukemia 21:44-52.
217. Ribatti D, Nico B, Spinazzi R, Vacca A, and Nussdorfer GG (2005) The role of adrenomedullin in angiogenesis. Peptides 26:1670-1675.
218. Ribatti D, Nico B, Vacca A, Roncali L, and Dammacco F (2002a) Endothelial cell heterogeneity and organ specificity. J Hematother Stem Cell Res 11:81-90.
219. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, and Dammacco F (1999a) Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-2636.
220. Ribatti D, Scavelli C, Roccaro AM, Crivellato E, Nico B, and Vacca A (2004) Hematopoietic cancer and angiogenesis. Stem Cell Dev 13:484-495.
221. Ribatti D, Vacca A, and Dammacco F (1999b) The role of vascular phase in solid tumor growth: a historical review. Neoplasia 1:293-302.
222. Ribatti D, Vacca A, and Presta M (2002b) The discovery of angiogenic factors: a historical review. Gen Pharmacol 35:227-231.
223. Ribatti D, Vacca A, Roccaro AM, Crivellato E, and Presta M (2003b) Erythropoietin as an angiogenic factor. Eur J Clin Invest 33:891-896.
224. Richard DE, Berra E, and Pouyssegur J (2000) Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1 in vascular smooth muscle cells. J Biol Chem 275:26765-26771.
225. Richardson JD and Vasko MR (2002) Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 302:839-845.
226. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674.
227. Rosanò L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, and Bagnato A (2001) Endothelin-1 induces proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61:8340-8346.
228. Rossert J and Eckardt KU (2005) Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant 20:1025-1028.
229. Rossi GP, Seccia TM, and Nussdorfer GG (2001) Reciprocal regulation of endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Int Rev Cytol 209:241-272.
230. Rubanyi GM and Polokoff MA (1994) Endothelins: molecular biology biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46:325-415.
231. Rück A, Gustafsson T, Norrbom J, Nowak J, Källner G, Söderberg M, Sylven C, and Drvota V (2004) ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium. Biochem Biophys Res Commun 322:287-291.
232. Rüegg C, Hasmim M, Lejeune FJ, and Alghisi GC (2006) Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim Biophys Acta 1765:155-177.
233. Rusnati M and Presta M (1996) Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Int J Clin Lab Res 26:15-23.
234. Saijonmaa O, Nyman T, and Fyhrquist F (1992) Endothelin-1 stimulates its own synthesis in human endothelial cells. Biochem Biophys Res Commun 188:286-291.
235. Salani D, Di Castro V, Nicotra MR, Rosanò L, Tecce R, Venuti A, Natali PG, and Bagnato A (2000a) Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157:1537-1547.
236. Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, Giavazzi R, and Bagnato A (2000b) Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 157:1703-1711.
237. Samson WK (1999) Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol 61:363-390.
238. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S, and Imaizumi T (2002) Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 109:603-611.
239. Schwarz N, Renshaw D, Kapas S, and Hinson JP (2006) Adrenomedullin increases the expression of calcitonin-like receptor and receptor activity modifying protein 2 mRNA in human microvascular endothelial cells. J Endocrinol 190:505-514.
240. Seegers HC, Hood VC, Kidd BL, Cruwys SC, and Walsh DA (2003) Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation. J Pharmacol Exp Ther 306:8-12.
241. Shah NM, Groves AK, and Anderson DJ (1996) Alternative neural crest cell fates are instructively promoted by TGFβ superfamily members. Cell 85:331-343.
242. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, and Walsh K (2004) Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J Biol Chem 279:28670-28674.
243. Shichiri M, Kato H, Marumo F, and Hirata Y (1997) Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 30:1198-1203.
244. Shichiri M, Yokokura M, Marumo F, and Hirata Y (2000) Endothelin-1 inhibits apoptosis of vascular smooth muscle cells induced by nitric oxide and serumdeprivation via MAP kinase pathway. Arterioscler Thromb Vasc Biol 20:989-997.
245. Shigeri Y and Fujimoto M (1993) Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neurosci Lett 149:19-21.
246. Shimizu T, Okamoto H, Chiba S, Matsui Y, Sugawara T, Akino M, Nan J, Kumamoto H, Onozuka H, Mikami T, et al. (2003) VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts. Cardiovasc Res 58:203-212.
247. Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, Imai Y, Ebihara A, Kuwaki T, Ju KH, et al. (2001) Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 104:1964-1971.
248. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, et al. (1998) Biological action of leptin as an angiogenic factor. Science 281:1683-1686.
249. Silberbach M and Roberts CR Jr (2001) Natriuretic peptide signaling. Molecular and cellular pathways to growth regulation. Cell Signal 13:221-231.
250. Silvestre JS, Tamarat R, Sebonmatsu T, Icchiki T, Ebrahimian T, Iglarz M, Besnard S, Durier M, Inagami T, and Levy BI (2002) Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res 90:1072-1079.
251. Simons M (2004) Integrative signaling in angiogenesis. Mol Cell Biochem 264:99-102.
252. Spinazzi R, Albertin G, Nico B, Guidolin D, Di Liddo R, Rossi GP, Ribatti D, and Nussdorfer GG (2006) Urotensin II and its receptor (UT-R) are expressed in rat brain endothelial cells and UII via UT-R stimulates angiogenesis in vivo and in vitro. Int J Mol Med 18:1107-1112.
253. Spinazzi R, Andreis PG, and Nussdorfer GG (2005) Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions. Int J Mol Med 15:3-13.
254. Spinella F, Rosanò L, Di Castro V, Natali PG, and Bagnato A (2002) Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J Biol Chem 277:27850-27855.
255. Spinella F, Rosanò L, Di Castro V, Natali PG, and Bagnato A (2004) Endothelin-1-induced prostaglandin E2-EP2,EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 279:46700-46705.
256. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, and Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307-312.
257. Stiles JD, Ostrow PT, Balos LL, Greenberg SJ, Plunkett R, Grand W, and Heffner RR Jr (1997) Correlation of endothelin-1 and transforming growth factor β1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 56:435-439.
258. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, and Unger T (1995) The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95:651-657.
259. Suhardja A and Hoffman H (2003) Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc Res Tech 60:70-75.
260. Sweeney G (2002) Leptin signaling. Cell Signal 14:655-663.
261. Taddei L, Chiarugi P, Brogelli L, Cirri P, Magnelli L, Raugei G, Ziche M, Granger HJ, Chiarugi V, and Ramponi G (1999) Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun 263:340-345.
262. Tait CR and Jones PF (2004) Angiopoietins in tumours: the angiogenic switch. J Pathol 204:1-10.
263. Taraboletti G, Roberts D, Liotta LA, and Giavazzi R (1990) Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 111:765-772.
264. Thurston G (2003) Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 314:61-68.
265. Tokunaga N, Nagaya N, Shirai M, Tanaka E, Ishibashi-Ueda H, Harada-Shiba M, Kanda M, Ito T, Shimizu W, Tabata T, et al. (2004) Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: benefits of a novel nonviral vector, gelatin. Circulation 109:526-531.
266. Touyz RM and Schiffrin EL (2000) Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52:639-672.
267. Tsuruda T, Kato J, Hatakeyama K, Yamashita A, Nakamura K, Imamura T, Kitamura K, Onitsuka T, Asada Y, and Eto T (2006) Adrenomedullin in mast cells of abdominal aortic aneurysm. Cardiovasc Res 70:158-164.
268. Turner HE, Harris AL, Melmed S, and Wass JAM (2003) Angiogenesis in endocrine tumors. Endocr Rev 24:600-632.
269. Vacca A and Ribatti D (2006) Bone marrow angiogenesis in multiple myeloma. Leukemia 20:193-199.
270. van der Lely AJ, Tschöp M, Heiman ML, and Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25:426-457.
271. van Hinsbergh VWM, Engelse MA, and Quax PHA (2006) Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26:716-728.
272. Vaudry D, Gonzales BJ, Basille M, Yon L, Fournier A, and Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to function. Pharmacol Rev 52:269-324.
273. A selective endothelin antagonist, in humans. Br J Clin Pharmacol 49:562-573.
274. Verma S, Li SH, Wang CH, Fedak PWM, Li RK, Weisel RD, and Mickle DAG (2003) Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108:736-740.
275. Vigne P, Marsault R, Breittmayer JP, and Frelin C (1990) Endothelin stimulates phosphatidylinositol hydrolysis and DNA synthesis in brain capillary endothelial cells. Biochem J 266:415-420.
276. von Tell D, Armulik A, and Betsholtz C (2006) Pericytes and vascular stability. Exp Cell Res 312:623-629.
277. Walsh DA, Hu DE, Wharton J, Catravas JD, Blake DR, and Fan TP (1997) Sequential development of angiotensin receptors and angiotensin II-converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma. Br J Pharmacol 120:1302-1311.
278. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, and Schirner M (2003) Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 17:2061-2067.
279. Wang H, Chen Z, and Anderson D (1998) Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93:741-753.
280. Watson JG, Balster DA, Gebhardt BM, O'Dorisio TM, O'Dorisio MS, Espenan GD, Drouant GJ, and Woltering EA (2001) Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 85:266-272.
281. Williams B, Baker AQ, Gallacher B, and Lodwick D (1995) Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25:913-917.
282. Wolf G (2003) Adiponectin: a regulator of energy homeostasis. Nutr Rev 61:290-292.
283. Wu-Wong JR, Chiou WJ, Dickinson R, and Opgenorth TJ (1997) Endothelin attenuates apoptosis in human smooth muscle cells. Biochem J 328:733-737.
284. Xia CF, Yin H, Borlongan CV, Chao J, and Chao L (2006) Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol 197:521-530.
285. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowi KC, Timpl R, and Olsen BR (1999) Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18:4414-4423.
286. Yamashita K (2001) Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1 activator protein-1, GATA-2 and p300/CBP. J Biol Chem 276:12645-12653.
287. Yoshimoto T, Matsushita M, and Hirata Y (2004) Role of urotensin II in peripheral tissues as an autocrine/paracrine growth factor. Peptides 25:1775-1781.
288. Zhang QX, Magovern C, Mack C, Budenbender K, Ko W, and Rosengart T (1997) Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res 67:147-154.
289. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, and Ledda F (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94:2036-2044.
290. Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, and Maggi CA (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 40:264-278.
291. Zudaire E, Martínez A, Garayoa M, Pio R, Kaur G, Woolhiser MR, Metcalfe DD, Hook WA, Siraganian RP, Guise TA, et al. (2006) Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol 168:280-291.
292. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, and Ji H (1998a) Mechanisms of vascular growth promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 75/ 76:231-238.
293. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, et al. (1998b) Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83:187-195.
294. Zukowska-Grojec Z, Pruszczyk P, Colton C, Yao J, Shen GH, Myers AK, and Wahlestedt C (1993) Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides 14:263-268.